Form 4: Chief Clinical Officer Removed from Section 16 Status
Statement of Changes in Beneficial Ownership
Jeffrey Langsam has been removed from the list of Section 16 officers at Oncology Institute, Inc. following a board decision.
Summary
- Jeffrey Langsam, the Chief Clinical Officer, is no longer classified as an officer for Section 16 reporting purposes.
- The change follows a Unanimous Written Consent of the Board of Directors dated April 21, 2026.
- No securities were bought or sold in connection with this update.
- The reporting person is no longer subject to Section 16 reporting obligations.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative adjustment to the company's reporting group.
Positives
- Streamlining of the executive reporting structure.
Negatives
- Loss of a key clinical executive from the Section 16 reporting group.
- Lack of clarity on the specific reasons for the change in officer status.
Risks
- Potential leadership transition risks within the clinical department.
- Uncertainty regarding whether the individual remains with the company in a non-officer capacity.
Future Outlook
No forward-looking statements or guidance were provided.
Management Comments
- Pursuant to a Unanimous Written Consent of the Board of Directors of the Issuer dated April 21, 2026, the reporting person was determined to no longer be an officer of the Issuer for purposes of Section 16.
Industry Context
StockSavvy.ai notes that changes in Section 16 status often occur when a company re-evaluates which executives hold significant policy-making roles, a common practice in maturing healthcare organizations.
Comparison to Industry Standards
- Standard administrative procedure for companies refining their list of Section 16 officers based on actual policy-making authority.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Clinical Officer | Jeffrey Langsam | N/A | 2026-04-21 | Board determination that the individual is no longer a Section 16 officer |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Officer Designation | Reclassification of the Chief Clinical Officer role regarding Section 16 status | 2026-04-21 | Reduces the number of individuals required to file public reports of their stock transactions. |
Stakeholder Impact
- Shareholders may see a reduction in transparency regarding the Chief Clinical Officer's personal stock transactions.
Next Steps
- Monitor for any subsequent 8-K filings regarding executive changes.
Key Dates
| Date | Description |
|---|---|
| 2026-04-21 | Board of Directors determination date |
| 2026-04-23 | Filing date of the Form 4 |
Keywords
Oncology Institute, TOI, Jeffrey Langsam, Chief Clinical Officer, Section 16, Executive Change, Healthcare Services
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.